Detection of Cause of Pink Discolouration Effect in Cheeses - Licensing Opportunity from Teagasc - October 2015 front page preview

Detection of Cause of Pink Discolouration Effect in Cheeses - Licensing Opportunity from Teagasc - October 2015

Teagasc is seeking partners within the diagnostics industry to exploit a novel qPCR-based test for supply of assay/kit for detection of the bacterial cause of pinking discolouration defect, to the dairy and cheese indust...

pdf 36.1KB

Rapid detection of toxin-encoding Bacillus Cereus - Licensing Opportunity from Teagasc - October 2015 front page preview

Rapid detection of toxin-encoding Bacillus Cereus - Licensing Opportunity from Teagasc - October 2015

Teagasc is seeking partners within the diagnostics industry to exploit a novel qPCR-based test capable of rapid, simultaneous detection of all Bacillus cereus toxin encoding genes (“CereusToxTest”), of benefit to the foo...

pdf 39.6KB

LithCTx - Combination drug therapy to prevent esophageal and lung cancers and cancer recurrence - Licensing Opportunity from University College Cork - September 2015 front page preview

LithCTx - Combination drug therapy to prevent esophageal and lung cancers and cancer recurrence - Licensing Opportunity from University College Cork - September 2015

A combination drug treatment comprising a chemotherapeutic drug and an autophagy inducing drug results in not only inhibition in the progression of cancer but also prevents the recurrence of cancer which may occur follow...

pdf 196.9KB

MirStent- cardiac repair therapy following heart attack - Licensing Opportunity from University College Cork - September 2015 front page preview

MirStent- cardiac repair therapy following heart attack - Licensing Opportunity from University College Cork - September 2015

After suffering a heart attack (i.e. STEMI type), a single dose IGF-1 therapy is effective in decreasing the size of the infarct (dead heart tissue) by at least 60%. Considering extensive use of stents in coronary angiop...

pdf 308.9KB

IL­‐36 Proteolytic Processing Inhibitors - A Enzyme Blocking Polypeptide front page preview

IL­‐36 Proteolytic Processing Inhibitors - A Enzyme Blocking Polypeptide

The development of a new and novel polypeptide entity that is capable of blocking the enzymes that promote inflammation of the skin such as psoriasis.

pdf 341.7KB